Alzex Neuropharma Inc.
TRRI
$0.12
$0.11889,900.00%
| 06/30/2011 | 03/31/2011 | 12/31/2010 | 09/30/2010 | 06/30/2010 | |
|---|---|---|---|---|---|
| Revenue | 912.90K | 930.50K | 877.70K | 1.24M | 738.40K |
| Total Other Revenue | 3.20K | -- | 30.70K | 2.40K | 2.80K |
| Total Revenue | 916.10K | 930.50K | 908.40K | 1.24M | 741.30K |
| Cost of Revenue | 787.80K | 906.20K | 768.30K | 1.11M | 645.10K |
| Gross Profit | 128.30K | 24.30K | 140.10K | 128.10K | 96.10K |
| SG&A Expenses | 161.80K | 34.20K | -8.90K | 106.60K | 91.50K |
| Depreciation & Amortization | 28.10K | 27.00K | -18.60K | 29.80K | 29.80K |
| Other Operating Expenses | -- | -- | -45.80K | -- | -- |
| Total Operating Expenses | 977.70K | 967.50K | 695.10K | 1.25M | 766.40K |
| Operating Income | -61.60K | -37.00K | 213.40K | -8.20K | -25.10K |
| Income Before Tax | -54.70K | -37.60K | 203.00K | -15.10K | -32.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -54.70K | -37.60K | 203.00K | -15.10K | -32.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.70K | -37.60K | 203.00K | -15.10K | -32.50K |
| EBIT | -61.60K | -37.00K | 213.40K | -8.20K | -25.10K |
| EBITDA | -33.40K | -10.00K | -- | -5.50K | 4.60K |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
